Role of PET/CT in Treatment Planning for Head and Neck Cancer Patients Undergoing Definitive Radiotherapy

Arslan, Sonay; Abakay, Candan Demiröz; Şen, Feyza; Altay, Ali Yılmaz; Akpinar, Tayyar; Ekinci, Ahmet; Eşbah, Onur; Uslu, Nuri; Kekilli, Kezban Esra; Özkan, Lütfi

doi:10.7314/apjcp.2014.15.24.10899

Cited by 7 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Similarly, Sonay found that GTV PET/CT was smaller than GTV-CT in 34 (92%) of 37 cases, while GTV-CT was smaller than GTV PET/CT in 3 cases. 22 In our study 3 months after treatment, PET/CT displayed a complete response in 21/25 (84%) patients and FDG avidity in 4/25 (16%) patients. A residual squamous cell carcinoma was found in only one patient out of four patients and was confirmed by biopsy.…”

Section: Discussionsupporting

confidence: 53%

“…In radiotherapy, it is crucial to precisely contour target organs and critical organs. 22 In our study, we reported statistically significant differences in gross target volume as assessed by 18F-FDG-PET/CT and CT in patients with HNC undergoing radiation therapy planning. PET/CT-GTV of the primary tumour was smaller in 23/30 (76•7%) patients and larger in 5/30 (16•7) patients than CT-GTV with statistically significant differences found between CT and PET/CT-based GTV (p-value = 0•023).…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Impact of FDG-PET/CT on restaging and response evaluation of locally advanced head and neck cancer patient management

et al. 2021

View full text Add to dashboard Cite

Background: Head and neck cancer (HNC) accounts for 5% of all new cancer cases and most were locally advanced. Positron emission tomography/computed tomography (PET/CT) in radiotherapy practice in locally advanced head and neck squamous cell carcinoma (HNSCC) is being used in staging and proper contouring. Proper staging is essential for accurate treatment decision. Methods: This is a prospective phase II study conducted as a single institute centre to evaluate the role of PET/CT-treatment in staging, contouring and response evaluation of 30 patients with locally advanced HNSCC in contrast to CT scan. Our cases did not undergo radical surgery for the primary tumour, and biopsy was taken with PET/CT post-treatment to evaluate response. Results: Median age of patients was 49·4 years (minimum age of 32 years and maximum of 68 years). Males were predominant 22 (73·3%). Nasopharynx was the predominant site 16/30 (53·3%). PET/CT changed the overall staging in 40% of the patients (upstaged in 36·7% and downstaged in 3·3%). Gross tumour volume (GTV) of PET/CT was smaller in 23 patients (76·7%) and larger in 5 (16·7%) than the GTV of conventional CT, whereas GTV of lymph nodes of PET/CT was larger in 20 patients (67·7%) and smaller in 4 (13·3%). PET/CT study detected bone metastasis in two nasopharyngeal carcinoma patients and two cases of 2nd primary tumours which were not detected using conventional CT. The Cox-regression model showed that the median standardised uptake volume (SUV) of the initial tumour had been a dependent predictor of death in patients with HNSCC (p-value = 0·033) where the risk of death was 0·725 times among patients with high SUV of the initial tumour. Consequently, the size of GTV of the tumour was significant in the prediction of death (p = 0·018). Conclusions: 18F-FDG-PET/CT is useful for staging, radiotherapy delineation as well as aiding proper decision making, in addition to assessment of treatment response in HNSCC patients.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 55%

Impact of FDG-PET/CT on restaging and response evaluation of locally advanced head and neck cancer patient management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a prospective trial, PET/CT was shown to enhance the precision of the radiation therapy target volume definition using the SUV of 2.5 or greater (threshold value of 40%) as compared to CT in NSCLC [ 30 – 32 ]. Analogously, Sonay et al assert that PET/CT can provide benefits in assessed target tumor volume for radiotherapy planning in patients with HNC [ 33 ]. In the present study, we also found that the SUV of 2.5 can reasonably guide the contouring of the GTV.…”

Section: Discussionmentioning

confidence: 99%

Biological target volume based on fluorine-18-fluorode-oxyglucose positron emission tomography/computed tomography imaging: a spurious proposition?

Yang

Hong

et al. 2023

Radiat Oncol

View full text Add to dashboard Cite

Purpose To assess whether the high metabolic region of fluorine-18-fluorode-oxyglucose (18F-FDG) in the primary lesion is the crux for recurrence in patients with nasopharyngeal carcinoma (NPC), to assess the feasibility and rationale for use of biological target volume (BTV) based on 18F-FDG positron emission tomography/computed tomography (18F-FDG-PET/CT). Methods The retrospective study included 33 patients with NPC who underwent 18F-FDG-PET/CT at the time of initial diagnosis as well as the time of diagnosis of local recurrence. Paired 18F-FDG-PET/CT images for primary and recurrent lesion were matched by deformation coregistration method to determine the cross-failure rate between two lesions. Results The median volume of the Vpri (primary tumor volume using the SUV thresholds of 2.5), the Vhigh (the volume of high FDG uptake using the SUV50%max isocontour), and the Vrecur (the recurrent tumor volume using the SUV thresholds of 2.5) were 22.85, 5.57, and 9.98 cm3, respectively. The cross-failure rate of Vrecur∩high showed that 82.82% (27/33) of local recurrent lesions had < 50% overlap volume with the region of high FDG uptake. The cross-failure rate of Vrecur∩pri showed that 96.97% (32/33) of local recurrent lesions had > 20% overlap volume with the primary tumor lesions and the median cross rate was up to 71.74%. Conclusion 18F-FDG-PET/CT may be a powerful tool for automatic target volume delineation, but it may not be the optimal imaging modality for dose escalation radiotherapy based on applicable isocontour. The combination of other functional imaging could delineate the BTV more accurately.

show abstract

“…79 By using FDG PET, the risk of inaccurately targeting radiation delivery to the intended volumes is reduced. 83,84 In addition, the use of other radiotracers, such as 18F-fluoromisonidazole, a biomarker for hypoxia, can identify tissues that require intensified treatment approaches. 85 Beyond PET biomarkers, functional MR imaging biomarkers provide the ability to characterize cellularity, vascularity, and permeability of tumors, thus leading to a more accurate representation of the biological tumor volume.…”

Section: Tumor Segmentationmentioning

confidence: 99%

PET/MR Imaging in Head and Neck Cancer

Becker,

de Vito,

Dulguerov

et al. 2023

Magnetic Resonance Imaging Clinics of North America

View full text Add to dashboard Cite

Role of PET/CT in Treatment Planning for Head and Neck Cancer Patients Undergoing Definitive Radiotherapy

Cited by 7 publications

References 14 publications

Impact of FDG-PET/CT on restaging and response evaluation of locally advanced head and neck cancer patient management

Impact of FDG-PET/CT on restaging and response evaluation of locally advanced head and neck cancer patient management

Biological target volume based on fluorine-18-fluorode-oxyglucose positron emission tomography/computed tomography imaging: a spurious proposition?

PET/MR Imaging in Head and Neck Cancer

Contact Info

Product

Resources

About